Drug Trial Radar · NCT01903109
Crossover Bioequivalence Study of Cevimeline 30 mg Capsules Under Fed Conditions
Last checked: Nov 20, 2026Latest source record: Jan 23, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
27
Actual
Start
Feb 2009
Primary completion
Feb 2009
Study completion Feb 2009
Sponsor
- Lead sponsor
- Roxane LaboratoriesIndustry
- Sponsor type
- Industry
- First posted
- Jul 19, 2013
Design
- Study type
- Interventional
- Phase
- Early phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The objective of this study was to prove the bioequivalence of Roxane Laboratories' Cevimeline 30 mg under fed conditions
Conditions
- Dry Mouth
Interventions
CevimelineDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- bioequivalence determined by statistical comparison CmaxTime frame: 33 Days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Novum Pharmaceutical Research Services
Las Vegas, Nevada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.